Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 408Rectal Neoplasms 152Colonic Neoplasms 150Pancreatic Neoplasms 112Stomach Neoplasms 110Neoplasm Metastasis 87Neoplasms 74Esophageal Neoplasms 60Small Cell Lung Carcinoma 45Neuroblastoma 42Lung Neoplasms 42Glioblastoma 38Carcinoma, Non-Small-Cell Lung 38Brain Neoplasms 33Esophageal Squamous Cell Carcinoma 32Unspecified Adult Solid Tumor, Protocol Specific 31Glioma 31Breast Neoplasms 28Central Nervous System Neoplasms 27Adenocarcinoma Of Esophagus 27Sarcoma 26Gliosarcoma 22Astrocytoma 22Rhabdomyosarcoma 21Sarcoma, Ewing 18Adenocarcinoma 18Gastrointestinal Neoplasms 17Oligodendroglioma 16Recurrence 14Biliary Tract Neoplasms 14

Interventions

Cetuximab 2Bevacizumab 2trifluridine tipiracil drug combination 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
mCRC × Irinotecan × Clear all
NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Peking University

Phase 2 Unknown
130 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡